United Therapeutics (NASDAQ: UTHR) reported Q3 EPS of $3.91, $1.94 better than the analyst estimate of $1.97. Revenue for the quarter came in at $330 million versus the consensus estimate of $335.1 million.

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.